Literature DB >> 19118456

Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice.

Raimund Trabold1, Sandro Krieg, Karsten Schöller, Nikolaus Plesnila.   

Abstract

Brain edema is still one of the most deleterious sequels of traumatic brain injury (TBI), and its pathophysiology is not sufficiently understood. The goal of the current study was to investigate the role of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), an important regulator of tissue water homeostasis, for the formation of post-traumatic brain edema, intracranial pressure (ICP), brain damage, and functional deficits following brain trauma. C57/B16 mice (n=112) were subjected to controlled cortical impact (CCI; 8m/s, 1 mm). At 3 min after trauma, animals received 500 ng of the AVP V(1a)-receptor antogonist (deamino-Pen(1), O-Me-Tyr(2), Arg(8)]-Vasopressin) or 500 ng of the AVP V2-receptor antagonist (adamantaneacetyl(1), O-Et-D-Tyr(2),Val(4), Abu(6),Arg(8,9)]-Vasopressin) by intracerebroventricular injection. After trauma, cerebral water content (24 h), ICP (24 h), contusion volume (24 h and 7 days), and functional outcome (1-7 days) were assessed (n=8 per experimental group). Post-traumatic inhibition of AVP V(1A) receptors reduced ICP by 29% (p < 0.05), brain water content by 45% (p < 0.05), and secondary contusion expansion by 37% (p < 0.05), and it significantly improved motor function 6 and 7 days after trauma (p < 0.05). Inhibition of AVP V2 receptors had no significant effect. The current results demonstrate that vasopressin V(1A) receptors are involved in the pathogenesis of brain edema formation and the subsequent development of secondary brain damage after traumatic brain injury. Accordingly, our study suggests that vasopressin V(1A) receptors may represent a novel therapeutic target for the treatment of post-traumatic brain edema and secondary brain damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118456     DOI: 10.1089/neu.2008.0597

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  32 in total

1.  Vasopressin amplifies the production of proinflammatory mediators in traumatic brain injury.

Authors:  Joanna Szmydynger-Chodobska; Leora M Fox; Kirsten M Lynch; Brian J Zink; Adam Chodobski
Journal:  J Neurotrauma       Date:  2010-08       Impact factor: 5.269

2.  Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: a new alternative?

Authors:  Jeremy D Fields; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-05-08       Impact factor: 3.210

3.  Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury.

Authors:  Christopher Galton; Steven Deem; N David Yanez; Michael Souter; Randall Chesnut; Armagan Dagal; Miriam Treggiari
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

4.  Vasopressin protects hippocampal neurones in culture against nutrient deprivation or glutamate-induced apoptosis.

Authors:  J Chen; G Aguilera
Journal:  J Neuroendocrinol       Date:  2010-10       Impact factor: 3.627

5.  Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice.

Authors:  Anatol Manaenko; Nancy Fathali; Nikan H Khatibi; Tim Lekic; Kenneth J Shum; Robert Martin; John H Zhang; Jiping Tang
Journal:  Acta Neurochir Suppl       Date:  2011

6.  A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury.

Authors:  Rajat Dhar; Theresa Murphy-Human
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

7.  Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury.

Authors:  Christina R Marmarou; Xiuyin Liang; Naqeeb H Abidi; Shanaz Parveen; Keisuke Taya; Scott C Henderson; Harold F Young; Aristotelis S Filippidis; Clive M Baumgarten
Journal:  Brain Res       Date:  2014-06-13       Impact factor: 3.252

8.  Vasopressin V1a Receptors Regulate Cerebral Aquaporin 1 after Traumatic Brain Injury.

Authors:  Katrin Rauen; Viorela Pop; Raimund Trabold; Jerome Badaut; Nikolaus Plesnila
Journal:  J Neurotrauma       Date:  2019-12-04       Impact factor: 5.269

9.  Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage.

Authors:  Christian Zweifel; Mira Katan; Philipp Schuetz; Martin Siegemund; Nils G Morgenthaler; Adrian Merlo; Beat Mueller; Mirjam Christ-Crain
Journal:  BMC Neurol       Date:  2010-05-26       Impact factor: 2.474

10.  Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4.

Authors:  Shin Nakayama; Mahmood Amiry-Moghaddam; Ole Petter Ottersen; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2016-04       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.